JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

Search

Eli Lilly and Co.

Avatud

SektorTervishoid

767.36 0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

759.04

Max

772.32

Põhinäitajad

By Trading Economics

Sissetulek

-6.1B

2.8B

Müük

-804M

13B

P/E

Sektori keskmine

60.989

51.198

Aktsiakasum

3.34

Dividenditootlus

0.8

Kasumimarginaal

21.678

Töötajad

47,000

EBITDA

-2B

4.2B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+30.26% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.80%

2.40%

Järgmine tulemuste avaldamine

6. aug 2025

Järgmine dividendimakse kuupäev

10. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-157B

671B

Eelmine avamishind

766.85

Eelmine sulgemishind

767.36

Uudiste sentiment

By Acuity

36%

64%

119 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2025, 14:41 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1. mai 2025, 11:24 UTC

Tulu

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29. mai 2025, 01:00 UTC

Peamised uudised

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28. mai 2025, 18:09 UTC

Tulu

Heart Disease Could Be a Goner When These New -2-

28. mai 2025, 18:09 UTC

Tulu

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27. mai 2025, 14:02 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27. mai 2025, 14:01 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27. mai 2025, 14:00 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27. mai 2025, 14:00 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20. mai 2025, 14:08 UTC

Tulu

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 17:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. mai 2025, 17:01 UTC

Peamised uudised

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. mai 2025, 13:56 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. mai 2025, 11:18 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6. mai 2025, 20:30 UTC

Peamised uudised

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4. mai 2025, 04:05 UTC

Omandamised, ülevõtmised, äriostud

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1. mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1. mai 2025, 14:07 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 12:47 UTC

Tulu

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1. mai 2025, 12:00 UTC

Peamised uudised

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1. mai 2025, 11:58 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 11:06 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 10:48 UTC

Tulu

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1. mai 2025, 10:48 UTC

Tulu

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q Adj EPS $3.34 >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q Net $2.76B >LLY

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

30.26% tõus

12 kuu keskmine prognoos

Keskmine 997.6 USD  30.26%

Kõrge 1,190 USD

Madal 700 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

17

Osta

2

Hoia

1

Müü

Tehniline skoor

By Trading Central

N/A / 884.54Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

119 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.